S241656

PreclinicalSmall molecule

Institut de Recherches Internationales Servier

S241656 is one of 76 small molecule programs targeting Malignancies. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalignanciesRecruiting

Acute Myeloid LeukemiaNot yet recruiting

MalignanciesPreclinical

Recruiting

Acute Myeloid LeukemiaPreclinical

Not yet recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Novantrone

Pfizer

Phase 3

34 3

Xospata

Astellas

Phase 3

24 4

Fludara

Sanofi

Phase 3

17 5

Vepesid

AAvyxa

Phase 3

52 6

Vanflyta

Daiichi Sankyo

Phase 3

14 7

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 8

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

30 9

Nexavar

Trexall

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Non-Small Cell Lung Cancer

NCT05786924

Q3 2030

PreclinicalNot yet recruiting

Acute Myeloid Leukemia

NCT07719348

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies

Recruiting· Institut de Recherches Internationales Servier logo

Institut de Recherches Internationales Servier·Preclinical·NCT05786924·554 enrolled

Acute Myeloid Leukemia1 trial

A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies

Not yet recruiting·SServier·Preclinical·NCT07719348·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for S241656. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — S241656 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for S241656. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut de Recherches Internationales Servier company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Institut de Recherches Internationales Servier

S241656

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q3 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News